Comparative Pharmacology
Head-to-head clinical analysis: AMINOHIPPURATE SODIUM versus XYLOSE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOHIPPURATE SODIUM versus XYLOSE.
AMINOHIPPURATE SODIUM vs XYLOSE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminohippurate sodium is a diagnostic agent used to measure effective renal plasma flow (ERPF) by competitive inhibition of tubular secretion of para-aminohippurate (PAH) via organic anion transporters (OAT1 and OAT3) in the proximal tubule, allowing clearance calculations.
Xylose is a pentose sugar that is absorbed in the small intestine via passive diffusion and active transport. It is used to assess intestinal mucosal integrity; its absorption reflects the function of the enterocytes. After absorption, it is not metabolized and is excreted unchanged in urine, making it a marker for intestinal absorption and renal function.
For measurement of effective renal plasma flow (ERPF): 0.2 mL/kg of a 20% solution (40 mg/kg) administered intravenously over 1-2 minutes, followed by continuous intravenous infusion of 0.5 mL/min of a solution containing 4.5 g aminohippurate sodium in 500 mL normal saline (9 mg/mL) to maintain stable plasma levels.
Adults: 25 g orally in 500 mL water, administered as a single dose for D-xylose absorption test.
None Documented
None Documented
Terminal elimination half-life is approximately 0.5–1.0 hour; used to measure effective renal plasma flow (ERPF).
Terminal elimination half-life: 1.2-2.5 hours in adults with normal renal function; prolonged in renal impairment (up to 10 hours).
Primarily renal: ~90% excreted unchanged by tubular secretion; <5% fecal.
Renal: approximately 85-90% eliminated unchanged in urine; biliary/fecal: negligible (<5%).
Category C
Category C
Diagnostic Agent
Diagnostic Agent